These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17006050)

  • 1. Valproate induced isolated neutropenia.
    Kohli U; Gulati S
    Indian J Pediatr; 2006 Sep; 73(9):844. PubMed ID: 17006050
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalized onycholysis associated with sodium valproate therapy.
    Grech V; Vella C
    Eur Neurol; 1999 Jul; 42(1):64-5. PubMed ID: 10523137
    [No Abstract]   [Full Text] [Related]  

  • 3. Valproate-induced worsening of seizures: clue to underlying diagnosis.
    Dhamija R; Gavrilova RH; Wirrell EC
    J Child Neurol; 2011 Oct; 26(10):1319-21. PubMed ID: 21454832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium valproate induced increased frequency of micturition and enuresis.
    Gosavi DD; Suman A; Jain M
    Indian J Pharmacol; 2013; 45(1):87-8. PubMed ID: 23543036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VII deficiency associated with valproate treatment.
    Unalp A; Dirik E; Kurul S
    Pediatr Int; 2008 Jun; 50(3):403-5. PubMed ID: 18533961
    [No Abstract]   [Full Text] [Related]  

  • 6. Urine Incontinence Induced by Valproic Acid.
    Sudan YS; Bansal AR
    Indian J Pediatr; 2017 Nov; 84(11):867-868. PubMed ID: 28577199
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutropenia during sodium valproate treatment.
    Jaeken J; van Goethem C; Casaer P; Devlieger H; Eggermont E; Pilet M
    Arch Dis Child; 1979 Dec; 54(12):986-7. PubMed ID: 119491
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine.
    Pantelis C; Adesanya A
    Aust N Z J Psychiatry; 2001 Aug; 35(4):544-5. PubMed ID: 11531743
    [No Abstract]   [Full Text] [Related]  

  • 9. Valproate-induced pseudoatrophy: expanding the clinical and imaging spectrum.
    Lovett M; Skidmore DL; Mohamed IS
    Pediatr Neurol; 2014 Aug; 51(2):284-5. PubMed ID: 25079580
    [No Abstract]   [Full Text] [Related]  

  • 10. Valproate-induced hyperammonemia as a cause of altered mental status.
    Feil D; Chuang K; Sultzer DL
    Am J Geriatr Psychiatry; 2002; 10(4):476-8. PubMed ID: 12095907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Neutropenia With Valproate and Quetiapine Combination Treatment in Subjects With Acquired Brain Injuries.
    Park HJ; Kim JY
    Arch Phys Med Rehabil; 2016 Feb; 97(2):183-8. PubMed ID: 26427579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity and valproate therapy.
    Betrosian A; Frantzeskaki F
    Intern Med J; 2006 Nov; 36(11):752-4. PubMed ID: 17040368
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents.
    Rahman A; Mican LM; Fischer C; Campbell AH
    Ann Pharmacother; 2009 May; 43(5):822-30. PubMed ID: 19401471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual cutaneous reaction with sodium valproate.
    Roy S; Goel D
    Neurol India; 2009; 57(2):216-7. PubMed ID: 19439862
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatic encephalopathy precipitated by sodium valproate therapy.
    Subhash HS; Heddle RJ; Schultz DW; Ring J; Thompson CH
    Med J Aust; 2008 May; 188(9):549. PubMed ID: 18459937
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial.
    Malamiri RA; Ghaempanah M; Khosroshahi N; Nikkhah A; Bavarian B; Ashrafi MR
    Eur J Paediatr Neurol; 2012 Sep; 16(5):536-41. PubMed ID: 22326977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologically mediated chronic tubulo-interstitial nephritis caused by valproate therapy.
    Fukuda Y; Watanabe H; Ohtomo Y; Yabuta K
    Nephron; 1996; 72(2):328-9. PubMed ID: 8684554
    [No Abstract]   [Full Text] [Related]  

  • 19. Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine.
    Rigamonti A; Lauria G; Grimod G; Bianchi G; Salmaggi A
    J Clin Neurosci; 2014 Apr; 21(4):690-1. PubMed ID: 24119342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
    Solomon GE
    Neurology; 2000 Aug; 55(4):606. PubMed ID: 10953214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.